Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials.

In 30 seconds

This randomized controlled trial pooled data from three phase 3 trials to assess the efficacy of mepolizumab in patients with chronic obstructive pulmonary disease (COPD) and varying blood eosinophil counts (BEC). Mepolizumab significantly reduced annualized rates of moderate or severe exacerbations by 21% in patients with BEC ≥300 cells/µL and showed reductions in other subgroups with elevated BEC.

Key findings

• Mepolizumab reduced annualized rates of moderate or severe exacerbations by 21% in patients with BEC ≥300 cells/µL.
• Patients with persistently elevated BECs experienced a 12%-27% reduction in exacerbations.
• Exacerbations requiring ED visits or hospitalization were reduced in patients with BEC starting from ≥150 cells/µL.
• No benefit was observed in patients with persistently low BEC (<150 cells/µL).

Why it matters

Understanding the role of blood eosinophil counts in COPD can help clinicians identify patients who may benefit from targeted therapies like mepolizumab, particularly those with type 2 inflammation.